Arkolith/Insider Trading/ZNTL/Form 4

Bruns Ingmar

Chief Medical OfficerZentalis Pharmaceuticals, Inc. (ZNTL) · full profile →Form 4 · filed Feb 10, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$8K
Net Open-Market Flow
-$8K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 9, 2026Sell(S)335$2.39$80133K
Feb 6, 2026Sell(S)3K$2.43$7K34K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001838041-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML